 |
 |
|
 |
||
 |
 |
|
 |
|
|
Last Updated: 6/18/2009
| E. Claire Dees, M.D.
Associate Professor |  |
Clinical Interests
Breast Cancer
Phase I Trials
Research Interests
Dr. Dees completed her internship and residency in internal medicine at the Brigham and Women's Hospital in Boston and her medical oncology fellowship training at the Johns Hopkins Oncology Center where she worked with the Phase I trials group and the breast cancer program. She has a masters degree in clinical trials research. She has been a member of the faculty at UNC since 1999. She is an active member of the UNC breast center and the leader of the Developmental Therapeutics Working Group at UNC. She is the Medical Director of the Clinical Protocol Office and the new Clinical Trials Unit in the North Carolina Cancer Hospital.
Dr. Dees's research focuses on breast cancer and novel therapeutics. She is also interested in studying inter-individual differences in chemotherapy associated toxicity. She is currently the lead investigator or co-investigator for a number of early phase clinical trials of new anti-cancer drugs and combinations for the treatment of patients with refractory solid tumors. She is also the principal investigator for several clinical trials of treatments specifically for early stage and metastatic breast cancer. She is the principal investigator for the cooperative group NSABP at UNC as well as a co-chair for several national trials through the cooperative group CALGB. She has been a member of the program planning committee for ASCO and sits on the editorial board of the Journal of Clinical Oncology. She has been awarded a Patient Oriented Research Career Development Award from the NIH and more recently an R21 grant for a phase I trial combining a targeted therapy with radiation. She has authored or co-authored over thirty-five articles.
Recent Accomplishments and Honors
Awards:
Doris Duke Clinical Scientist Career Development Award
NIH K23 Career Development Award
R21 Quick Trials for Novel Cancer Therapies Award
Training
Duke University M.D. 1993
Board Certifications
Internal Medicine 1996
Medical Oncology 1998
Publications
Selected publications
Dees, E.C., Shulman, L.N., Souba, W.W., and Smith, B.L. Does Information From Axillary Dissection Change Treatment in Clinically Node-Negative Patients with Breast Cancer? An Algorithm for Assessment of the Impact of Axillary Dissection. Annals of Surgery 1997: 226(3): 279-287.
Dees, E.C., O'Reilly, S., Goodman, S., Sartorius, S., Levine, M.A., Jones, R.J., Grochow, L.B., Donehower, R.C., Fetting,J.H. A Prospective Pharmacologic Evaluation of Age-related
Toxicity of Adjuvant Chemotherapy in Women with BreastCancer. Cancer Investigation 2000: 18(6); 521-529.
Dees, E.C., Whitfield, L.R., Grove, W.R., Rummel S., Grochow,L.B., Donehower, R.C. A Phase I and Pharmacologic Evaluation of the DNA Intercalator CI-958 in Patients with Advanced Solid Tumors. Clin Cancer Res.,2000: 6; 3885-3894.
Dees, E.C., Rowinsky, E.K., Noe, D.A., O'Reilly, S., Adjei, A., Elza-Brown, K., Donehower, R.C. A Phase I and Pharmacologic Study of Pyrazoloacridine and Cisplatin in Patients with Advanced Cancer. Investigational New Drugs 2003: 21, 75-84.
Dees, E.C., McKinnon K.P., Kuhns, J.J., Chwastiak, K.A., Sparks, S., Myers, M., Collins, E.J., Frelinger, J.A., VanDeventer, H., Collichio, F., Carey, L., Brecher, M., Graham, M., Earp, H.S., Serody J.S. Dendritic Cells Can Be Rapidly Expanded ExVivo and Safely Administered in Patients with Metastatic Breast Cancer. Cancer Immunology and Immunotherapy 2004.
Carey, L.A., Ewend, M.G., Metzger, R., Sawyer, L., Dees, E.C., Sartor, C.I., Moore, D.M., Graham, M.L. Central nervous system metastases in women after multimodality therapy for high risk breast cancer. Breast Cancer Research and Treatment 2004: 88(3) 273-280.
Orlowski, R Z, Voorhees, P.M., Garcia, R.A., Hall, M.D., Kudrick, F.J., Allred, T., Johri, A., Jones, P.E., VanDeventer, H.W., Gabriel, D.A., Shea, T.C., Mitchell, B.S., Adams, J., Esseltine, D., Trehu, E.G., Lehman, M.J., Natoli S., Collins, J.M., Lindley, C.M., Dees E.C. Phase I Trial of the Proteasome Inhibitor Bortezomib and Pegylated Liposomal Doxorubicin in Patients with Advanced Hematologic Malignancies. Blood 2005; 105(8): 3058-65.
Spector N, Xia W, Burris H, Hurwitz H, Dees EC, Dowlati A, O'Neil B, Overmoyer B, Marcom PK, Blackwell KL, Smith DA, Kock KM, Stead A, Mangum S, Ellis MJ, Liu L, man AK, Bremer TM, Harris J, Bacus S. Study of the biological effects of lapatinib, a reversible inhibitor of EGFR and ErbB2 tyrosine kinases , on tumor growth and survival pathways in patients with advanced malignancies. J Clin Oncol 2005; 23 (11): 2502-12.
Dees, E.C., Baker, S.B., O'Reilly, S., Figg, W.D., Elza-Brown, K., Aylesworth, C., Carducci, M.A., Donehower, R.C. A Phase I and Pharmacologic Study of UCN-01. Clin Cancer Res 2005;11:664-671.
Dees, EC, Watkins PB. The Role of CYP Phenotyping in Cancer Treatment (edit). J Clin Oncol, 2005; 23:1053-55.
Burris HA, Hurwitz HI, Dees EC, Dowlati A, Blackwell KL, O'Neil B, Marcom PK, Ellis MJ, Overmoyer B, Jones SF, Harris JL, Smith DA, Koch KM, Stead A, Mangum S, Spector NL. Phase I Safety Pharmacokinetics and Clinical Activity Study of Lapatinib(GW572016), a Reversible Dual Inhibitor of Epidermal Growth Factor Receptor Tyrosine Kinases in Heavily Pretreated Patients with Metastatic Carcinomas. J Clin Oncol 2005 Aug 10; 23(23): 5305-13.
Carey LA, Metzger R, Dees EC, et al. AJCC TNM stage after neoadjuvant chemotherapy and breast cancer outome. J Natl Cancer Inst. 2005 Aug 3; 97(15):1137-42.
Blum J, Dees EC, Chacko A, Doane L, et al. Phase II trial of capecitabine and weekly paclitaxel as first line therapy for metastatic breast cancer. J Clin Oncol. 2006 Sep 20;24(27):4384-90.
Gilbert J, Carducci MA, Dees EC, Baker SD, Donehower R. A Phase I Study of the Oral Antimetabolite, CS-682, Administered Once Daily 5 Days Per Week in Patients with Refractory Solid Tumor Malignancies. Investigational New Drugs 2006, Invest New Drugs. 2006 Nov;24(6):499-508
Kelly H, Kimmick G, Dees EC, Collichio F, Gatti L, Sawyer L, Ivanova A, Dressler L, Graham ML, Carey LA. Response and cardiac toxicity of trastuzumab given in conjunction with weekly paclitaxel after doxorubicin/cyclophosphamide. Clin Breast Cancer 2006; 7(3): 237-243.
Kelly H, Graham M, Humes E, Dorflinger LJ, Boggess K, Oneil BH, Harris J, Spector NL, Dees EC. Delivery of a Healthy Baby following first trimester maternal exposure to EGFR and HER2 inhibitor lapatinib. Clinical Breast Cancer 2006, Oct; 7(4): 339-41.
Ryan DP, O’Neil B., Rocha Lima C, Supko J, Dees EC, Appleman L, Fishman M, Clark J, Fidias P, Keane J, Nix D, Esseltine D, Kashala O, Schenkein D, Lynch T, Eder J P, Cusack J. A Phase I Study of Bortezomib Plus Irinotecan in Patients with Advanced Solid Tumors. Cancer 2006Dec 1: 107(11):2688-97
Carey LA, Dees EC, Sawyer L, Gatti L, Moore DT, Collichio F, Ollila DW, Sartor CI, Graham ML, Perou CM. The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes. Clin Cancer Res 2007; 13(8) 2329-34.
Stinchcombe TE, Socinski MA, Walko CM, O’Neil BH, Collichio FA, Ivanova A, Mu H, Hawkins MJ, Lindley CM, Dees EC. Phase I and Pharmacokinetics Trial of the Combination of Carboplatin and Albumin-bound Paclitaxel, ABI-007, on Three Treatment Schedules. Cancer Chemotherapy and Pharmacology 2007 epub
Blum JL, Dees EC, Vukelja SJ, Amare M, Gill DP, McMahon RT, Ilegbodu D, Asmar L, O'Shaughnessy JA. Phase II trial of capecitabine and weekly paclitaxel in patients with metastatic breast cancer previously treated with every-3-week taxane therapy. Clin Breast Cancer. 2007;7(6):465-470.
Partridge AH, Winer JP, Sampson E, Blood E, Dees C, Emmons K, Winer EP. Attitudes and management approaches of physicians who care for women with DCIS. Clin Breast Cancer. 2008 Jun;8(3):275-80.
Partridge A, Adloff K, Blood E, Dees EC, Kaelin C, Golshan M, Ligibel J, de Moor JS, Weeks J, Emmons K, Winer
E. Risk perceptions and psychosocial outcomes of women with ductal carcinoma in situ: longitudinal results from a cohort study. Journal of the National Cancer Institute 2008 Feb 20; 100(4): 243-51. Epub 2008 Feb 12.
Ngo N, Yan Z, Graf TN, Carrizosa DR, Kashuba AD, Dees E.C.,Oberlies NH, Paine MF, Identification of a cranberry juice product that inhibits enteric CYP3A-mediated first-pass metabolism in humans. Drug Metab Dispos. December 2008. Epub ahead of print}
Dees EC, O’Neil BH, Lindley CM, Collichio F, Carey F, Humes E, Collins J, Riordan WJ, Ivanova A, Esseltine D, Schenkein D, Orlowski RZ. A Phase I and Pharmacologic Study of the Combination of Bortezomib and Pegylated Liposomal Doxorubicin in Patients with Refractory Solid Tumors. Cancer Chemother Pharmacol. 2008 Mar 8. [Epub ahead of print]
Stinchcombe TS, Socinski MA, Lee CB, Hayes DN, Moore DT, Goldberg RM, Dees EC. Phase I trial of nanoparticle albumin-bound paclitaxel (nabpaclitaxel) in combination with gemcitabine in patients with thoracic malignancies. J Thoracic Oncology 2008:3(5);521-6.
Miller AA, Murry Dj, Owzar K, Hollis DR, Kennedy EB, Abou-Alfa G, Desai A, Hwang J, Villalona-Calero MA, Dees EC, Lewis LD, Fakih MG, Edelman MJ, Millard F, Frank RC, Hohl RJ, Ratain MJ. Phase I and Pharmacokinetic Study of sorafenib in Patients With Hepatic or Renal Dysfunction: CALGB 60301. J Clin Oncol. March 2009. [Epub ahead of print]
E-mail: claire_dees@med.unc.edu
Telephone: (919) 966-4431
FAX: (919) 966-6735
Address: Chapel Hill, NC
